Welcome to our dedicated page for RxSight news (Ticker: $RXST), a resource for investors and traders seeking the latest updates and insights on RxSight stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RxSight's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RxSight's position in the market.
RxSight, Inc., a medical device company specializing in vision care post cataract surgery, announced the pricing of its public offering of common stock. The company plans to sell 1,785,714 shares at $56.00 per share, expecting gross proceeds of approximately $100.0 million. The offering is set to close around May 13, 2024, with plans to utilize the funds for commercial expansion, product development, research, and general corporate purposes.
RxSight, Inc. announced a proposed public offering of $100 million of its common stock, with an additional 15% option for underwriters. The company plans to use the proceeds for commercial expansion, product development, research, and working capital. BofA Securities, J.P. Morgan, and BTIG are involved in the offering. An automatic shelf registration statement was filed with the SEC. The offering will be made through a prospectus supplement and accompanying prospectus.
RxSight, Inc. reported strong first quarter 2024 financial results, with a revenue of $29.5 million, a 69% increase compared to the first quarter of 2023. The company sold 20,218 Light Adjustable Lenses (LAL) and 66 Light Delivery Devices (LDD), showing significant growth in procedure volume and unit sales. Gross profit increased to $20.7 million, operating expenses rose to $31.4 million, and the company reported a net loss of $(9.1) million. However, adjusted net loss improved to $(4.4) million. Cash, cash equivalents, and short-term investments were $125.4 million as of March 31, 2024. RxSight raised its 2024 revenue guidance to $132.0 million to $137.0 million, gross margin guidance to 68% to 70%, and operating expense guidance to $126.0 million to $130.0 million.
RxSight, Inc., a medical device company specializing in customized vision after cataract surgery, will be presenting at the Bank of America Healthcare Conference on May 15, 2024. The presentation will be available for viewing online.
